About Empower At Empower, we believe healthcare should be personal, affordable, and accessible to everyone
It is not intended to diagnose, treat, cure, or prevent any disease.
*Safety info: GLP-1 drugs may have serious side effects, including possible thyroid tumors
Nausea (most common, typically dose-dependent and transient) Diarrhea or constipation during dose escalation Vomiting, especially when starting or increasing dose Reduced appetite and early satiety Injection site reactions (redness, bruising) Fatigue, particularly in early weeks Rare: Pancreatitis discontinue immediately with severe abdominal pain Rare: Thyroid C-cell effects (contraindicated with MEN2 or thyroid cancer history) Retatrutide (LY3437943) is Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist in Phase III clinical trials
For sub-10 unit doses, consider a 0.3 mL insulin syringe
Does Wegovy Have a Golden Dose